157 related articles for article (PubMed ID: 20375802)
1. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women.
Konno R; Sasagawa T; Fukuda T; Van Kriekinge G; Demarteau N
Int J Gynecol Cancer; 2010 Apr; 20(3):385-92. PubMed ID: 20375802
[TBL] [Abstract][Full Text] [Related]
2. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
Demarteau N; Tang CH; Chen HC; Chen CJ; Van Kriekinge G
Value Health; 2012; 15(5):622-31. PubMed ID: 22867770
[TBL] [Abstract][Full Text] [Related]
6. Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea.
Lee H; Hur S; Jang H; Lee IH; Sohn WY; Van Kriekinge G; Kim BG
Asian Pac J Cancer Prev; 2019 Feb; 20(2):425-435. PubMed ID: 30803204
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia.
Ezat WP; Aljunid S
Asian Pac J Cancer Prev; 2010; 11(1):79-90. PubMed ID: 20593935
[TBL] [Abstract][Full Text] [Related]
8. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.
Van Kriekinge G; Sohn WY; Aljunid SM; Soon R; Yong CM; Chen J; Lee IH
Asian Pac J Cancer Prev; 2018 Apr; 19(4):933-940. PubMed ID: 29693347
[TBL] [Abstract][Full Text] [Related]
9. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.
Kulasingam SL; Myers ER
JAMA; 2003 Aug; 290(6):781-9. PubMed ID: 12915431
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
11. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
Li X; Stander MP; Van Kriekinge G; Demarteau N
BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
[TBL] [Abstract][Full Text] [Related]
13. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.
Anonychuk AM; Bauch CT; Merid MF; Van Kriekinge G; Demarteau N
BMC Public Health; 2009 Oct; 9():401. PubMed ID: 19878578
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
15. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
16. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S
Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870
[TBL] [Abstract][Full Text] [Related]
17. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
[TBL] [Abstract][Full Text] [Related]
18. Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis.
Georgalis L; de Sanjosé S; Esnaola M; Bosch FX; Diaz M
Eur J Cancer Prev; 2016 Sep; 25(5):430-9. PubMed ID: 26375246
[TBL] [Abstract][Full Text] [Related]
19. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.
Yamamoto N; Mori R; Jacklin P; Osuga Y; Kawana K; Shibuya K; Taketani Y
BJOG; 2012 Jan; 119(2):177-86. PubMed ID: 21794070
[TBL] [Abstract][Full Text] [Related]
20. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
